The in vitro activity of a new semisynthetic penicillin, piperacillin, was determined against 577 clinical isolates of gram-positive cocci and gram-negative bacilli. A concentration of 12.5 ug/ml inhibited 92% of isolates of Pseudomonas aeruginosa, 82% of Serratia marcescens, 73% of Escherichia coli, 61% of Klebsiella spp., and 42% of Enterobacter spp. Most Proteus spp. were extremely susceptible; over 85% were inhibited by 0.10 ug/ml. Piperacillin failed to inhibit the growth of gram-negative bacilli when large inocula were used. (3, 6) . No antibiotic has been entirely satisfactory for treatment of these infections. The aminoglycosides provide broad-spectrum activity but are associated with nephrotoxicity and appear to be somewhat less effective in compromised hosts (2, 8) . Penicillins are less toxic, but most derivatives have a limited spectrum of activity. Consequently, new analogs are being synthesized and evaluated. Piperacillin [sodium 6-{D(-)-a-(4 ethyl-2,3-dioxo-1-piperazinylcarbonylamino)-a phenylacetamido)penicillanate] is a new semisynthetic penicillin with broad-spectrum activity. This report presents an in vitro evaluation of piperacillin and compares its activity with other semisynthetic penicillins.
Infection continues to be a major cause of morbidity and mortality among hospitalized patients. Many of these infections are caused by gram-negative bacilli. Escherichia coli, Klebsiellapneumoniae, and Pseudomonas aeruginosa are responsible for the majority of gram-negative bacillary infections in most hospitals, although epidemics caused by other organisms including Serratia marcescens and Proteus spp. have been recognized in recent years (3, 6) . No antibiotic has been entirely satisfactory for treatment of these infections. The aminoglycosides provide broad-spectrum activity but are associated with nephrotoxicity and appear to be somewhat less effective in compromised hosts (2, 8) . Penicillins are less toxic, but most derivatives have a limited spectrum of activity. Consequently, new analogs are being synthesized and evaluated. Piperacillin [sodium 6-{D(-)-a-(4 ethyl-2,3-dioxo-1-piperazinylcarbonylamino)-a phenylacetamido)penicillanate] is a new semisynthetic penicillin with broad-spectrum activity. This report presents an in vitro evaluation of piperacillin and compares its activity with other semisynthetic penicillins.
MATERIALS AND METHODS
Susceptibility tests were conducted on 471 clinical isolates of gram-negative bacilli and 106 clinical isolates of gram-positive cocci, using a dilution technique with an automatic microtiter system (Canalco Inc., Rockville, Md., autotiter instruction manual). All gram-negative bacilli and Staphylococcus aureus isolates tested were incubated in Mueller-Hinton broth (pH 7.4) for 18 h at 37°C. Streptococcus pyogenes and Streptococcus pneumoniae were incubated in tryptose phosphate broth. Approximately 105 colony-forming units (CFU)/ml were used in inoculum for gram-negative bacilli and S. aureus. For the remaining grampositive cocci, an inoculum of 10' CFU/ml was used for the in vitro susceptibility tests.
All gram-negative bacilli used in this study were cultured from blood specimens of patients who were hospitalized at this institution and had underlying malignant diseases. A total of 100 isolates each of P. aeruginosa, Klebsiella spp., and E. coli, 56 isolates of Proteus spp., 36 isolates of Serratia spp., and 79 isolates of Enterobacter spp. were used. All grampositive cocci used in this study were cultured from specimens obtained from hospitalized patients, most of whom did not have cancer. A total of 50 isolates of S. pyogenes, 7 isolates of S. pneumoniae, and 49 isolates of S. aureus was used. Isolates of S. aureus were divided according to their susceptibility to penicillin G. Those isolates which were inhibited by less than 0.10 ltg/ml were selected as penicillin G susceptible, and those isolates resistant to more than 25 ug/ml were selected as penicillin G resistant.
Organisms used for studies of the effect of inoculum size on the activity of piperacillin were incubated in Mueller-Hinton broth for 18 h at 370C. It was assumed that approximately 108 CFU/ml were present after incubation, which was subsequently confirmed by subculturing 0.1-ml aliquots on sheep blood agar and performing colony counts after 24 h of incubation at 37°C. Serial 10-fold dilutions of the broth culture were made, using Mueller-Hinton broth, so that 107 and 105 CFU/ml were used as inocula. An inoculum of 105 CFU/ml was used in all other studies of gram-negative bacilli. Studies of the effect of pH on the activity of isolates of indole-positive Proteus spp. were used. Isolates were selected so that organisms with differing susceptibilities to piperacillin were included.
Piperacillin was supplied as a white powder by Lederle Laboratories, Pearl River, N.Y. Azlocillin and mezlocillin were supplied as powders by Delbay Pharmaceuticals Inc., Bloomfield, N.J. Carbenicillin and ticarcillin were supplied by Beecham Pharmaceuticals, Bristol, Tenn. PC-904 was supplied by Sumitomo Chemical Co. Ltd., Hyogo, Japan. All antibiotics were diluted serially in Mueller-Hinton broth or tryptose phosphate broth. No visible growth after 18 h of incubation at 370C was accepted to be the minimal inhibitory concentration (MIC). The minimum bactericidal concentration (MBC) was defined as the lowest concentration of drug which yielded less than five colonies on subculture to sheep blood agar (99% kill). A 0.01-ml calibrated pipette was utilized to transfer the inoculum. Comparative studies were performed simultaneously in triplicate. Figure 1 summarizes the in vitro activity of piperacillin against gram-positive cocci and gram-negative bacilli. All gram-positive cocci, except penicillin G-resistant S. aureus, were inhibited by 0.78 ,ug/ml. The majority of the latter organisms were resistant to 25 ,g of piperacillin. per ml. Most Proteus spp. were quite susceptible to piperacillin; a concentration of 0.10 ,ug/ml inhibited 85% indole-positive Proteus spp. and 92% of P. mirabilis. A majority of most species of gram-negative bacilli were inhibited by 12.5 ,ug of this antibiotic per ml. At this concentration, 92% of P. aeruginosa, 82% of S. marcescens, 73% of E. coli, 61% of Klebsiella spp., and 42% of Enterobacter spp. were inhibited. The MBC was the same as the MIC for most organisms. For the exceptions, the MBC was twofold higher than the MIC.
RESULTS
The effect of inoculum size on the MIC for 10 isolates each of E. coli, K. pneumoniae, and P. aeruginosa were determined. All of the isolates of E. coli, nine of the isolates of P. aeruginosa, and eight of the isolates of K. pneumoniae were inhibited by 12.5 ,ug of piperacillin per ml when an inoculum of 105 CFU/ml was used. However, when an inoculum of 107 CFU/ml was used, none of the isolates was inhibited by 400 ,ug/ml.
The effect of pH and media variation was ascertained for 10 isolates of E. coli, K. pneumoniae, and P. aeruginosa. Piperacillin was more active against E. coli and K. pneumoniae (Fig. 2) (Fig. 3) against E. coli and K. pneumoniae in various media were miniimal. However, the difference between the activities of piperacillin against P. aeruginosa in nutrient broth and brain heart infusion broth were substantial.
The susceptibility of isolates of Enterobacteriaceae to piperacillin, carbenicillin, ticarcillin, amoxicillin, PC-904, mezlocillin, and azlocillin was determined. PC-904 was the most active penicillin against isolates of E. coli (Fig. 4) . However, mezlocillin and piperacillin were only slightly less active, and the greater activity of PC-904 was only demonstrable against isolates inhibited by 50.78 Ag/ml. PC-904 also was the most active penicillin against isolates of Klebsiella spp. (Fig. 5) Piperacillin was the most active penicillin against isolates of S. marcescens (Fig. 6 ). Mezlocillin and PC-904 also had considerable activity; nearly 90% of isolates were inhibited by 100 jig of these three penicillins per ml. Over 40% of these isolates were resistant to 400 jig of amoxicillin, carbenicillin, and ticarcillin per ml. Mezlocillin was the most active penicillin against Enterobacter spp., but piperacillin and PC-904 demonstrated only slightly less activity (Fig. 7) . However, 20 to 30% of these isolates were resistant to 400 ytg of these three penicillins per ml. (Fig. 8) . Against indole-positive isolates, it was eight times more active than carbenicillin, which was the second most active penicillin. It was also two to eight times more active than other penicillins against P. mirabilis. Figure 9 illustrates the activity of the 7 penicillins against 50 isolates of P. aeruginosa. PC-904 was the most active penicillin, eight times more active than piperacillin against most isolates. Piperacillin was 2 times as active as azlocillin, 4 penicillins which has broad-spectrum activity against E. coli, K. pneumoniae, S. marcescens, Proteus spp., and P. aeruginosa. . Ives et al. found E. coli to be less susceptible to piperacillin than other gram-negative bacilli, whereas piperacillin was quite active against most of our isolates of E. coli. Although they used different media, Ueo et al. obtained results which were similar to the results of our studies (7) . Both the type of culture medium and pH had little effect on the in vitro activity of piperacillin in both studies. They also found that the MBC was the same as the MIC for most organisms. However, for penicillinaseproducing strains of Klebsiella spp., Proteus spp., and P. aeruginosa, the MBC was four to eight times higher than the MIC.
Inoculum size had a major effect on the activ-
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. ity of piperacillin. Like azlocillin and PC-904, piperacillin was inactive against inocula of E. coli, P. aeruginosa, and K. pneumoniae containing 107 CFU. Several investigators have reported this adverse effect oflarge inocula on the activity of other semisynthetic penicillins (4, 5) . The clinical importance of this observation is not clear, but it has been suggested that this is due to the presence of a greater number of resistant cells in the larger inocula.
Piperacillin is an interesting new semisynthetic penicillin of potential importance. Not only is it more active in vitro than most other penicillins against gram-negative bacilli, but it encompasses a broader spectrum of activity. It is active against the Klebsiella-Enterobacter-Serratia group and has substantially greater activity against P. aeruginosa than carbenicillin and ticarcillin.
